ArticleJournal, genetic engineering & biotechnology2026
A comprehensive in silico investigation into the deleterious nonsynonymous single nucleotide polymorphisms of the human transcription factor EB (TFEB) gene and their predicted association with cancer.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcription factor EB (TFEB) is an essential protein that is connected to a number of diseases, such as lysosomal storage disorders and cancer. Patients with glioblastoma multiforme and uterine endometrioid carcinoma have already been identified to have nonsynonymous mutations in this gene. These mutations may have an impact on TFEB protein's functions and structure. Therefore, to find possible biomarkers for different disease treatments, the most harmful single nucleotide polymorphisms (SNPs) of the TFEBprotein have been identified in this study. The goal is to create a systematic dataset of the SNPs related to the TFEBgene, which could be useful in the diagnosis and management of many disorders linked to the target gene. The SNPs of the TFEBprotein were analyzed via a wide range of bioinformatics techniques, including both sequence and structure-based methodologies. Nonsynonymous SNV research can be advanced through the application of various machine learning methods that have been developed as a result of recent advancements in computational platforms. Among 449 nsSNPs, a total of 6 nsSNPs have been found to be harmful, destabilizing, and disease-causing. Each nsSNP interferes with its function. All of the mutant proteins interact with the DNA molecule during docking more effectively than the alphafold (wild type) protein does. A strong correlation between cancer and mutations in R315 has been identified. The detrimental effects of nsSNPs and noncoding SNPs on the structure and activities of proteins will help researchers understand the crucial role that mutations play in the molecular pathways involved in a variety of disorders. The discovery of possible targets for the diagnosis of diseases and treatment interventions will eventually result from this. Moreover, this thorough analysis can facilitate the exploration of potential disease-causing SNPs in the TFEB gene and assist in identifying effective drugs or pharmacological targets. Consequently, further experimental mutational research, genome-wide association studies, and clinical-based studies are essential to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.